New breast cancer vaccine provides evidence of immunotherapy in preventing disease re
 

A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.

More...

Re: New breast cancer vaccine provides evidence of immunotherapy in preventing diseas
 

I liked this line:

So ladies, are we looking at high cure rates with these vaccines? It appears so. Not only the early stage Her2 3+ with GP2, but the subset of triple negative with low Her2 expression might also reach high cure rates with the E75. I expect good news from AE37 as well.

We lucky ladies who entered these trials need to stay in touch with the trial administrators. I personally would like to see data beyond 5 years.

Re: New breast cancer vaccine provides evidence of immunotherapy in preventing diseas
 

I checked the dates for the phase II, both AE37 & GP2:

Estimated Enrollment: 600 Study Start Date: January 2007 Estimated Study Completion Date: December 2015 Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
I'm only familiar with E75 being in Phase III. If anyone gets news about a Phase III for AE37 or GP2 please share.

Re: New breast cancer vaccine provides evidence of immunotherapy in preventing diseas
 

I am in the phase 2 of the GP2 vaccine trial from Walter reed. I know they reached their enrollment goal and my admin nurse said she is waiting to hear in phase 3 will begin soon. I was HER2+ (+3), so this news is amazing and I am so glad I did the trial.

Re: New breast cancer vaccine provides evidence of immunotherapy in preventing diseas
 

I'm 3 years ahead of you in the trial.

I had hoped that the Phase III for AE37 & GP2 would have started earlier so that more of us could have enrolled, especially with such good news. I will be so flippin relieved when the Phase III starts - I expect and hope the vaccines will be available in numerous, more accessible trial locations.

Re: New breast cancer vaccine provides evidence of immunotherapy in preventing diseas
 

This is indeed exciting news; I wish I could have been on the trial.

So what is the Phase III part of a trial? Will they enroll new patients or just continue following the original cohort?

Also, 'Lizbeth, do you know if the vaccines have to be administered within a certain length of time after completing treatment with Herceptin? I'm just wondering if this will impact those of us who finished treatment already.

Shirley

Re: New breast cancer vaccine provides evidence of immunotherapy in preventing diseas
 

Shirley, to answer part of your question. This is the reason for the different Phases of a clinical trial:

Re: New breast cancer vaccine provides evidence of immunotherapy in preventing diseas
 

Thank you!

Re: New breast cancer vaccine provides evidence of immunotherapy in preventing diseas
 

If we are fortunate enough to have a Phase III trial for the Her2 higher expressors it will be with all new enrollees. I hope that we Phase IIs will continue to be followed.

When I enrolled in the Phase II, I had expected a Phase III to start for the Her2 survivors. Along the way, the primary companies switched focus from us to the lower expressors. There are Phase III trials currently for Her2 1+ and Her2 2+, but nothing for the Her2 3+ that I am aware of.

I thought that Dr. Mittendorf was working on something for the higher expressors with E75, and I hope so. I would also like to see Antigen Express start a Phase III for the higher expressors with AE37, and Dr. Peoples with GP2.

When I enrolled in the AE37/GP2 trial the window was to be enrolled 6 months from the completion of Herceptin.